The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology

Research output: Contribution to journalReview articlepeer-review

52 Citations (Scopus)
134 Downloads (Pure)

Abstract

Cell therapy with polyclonal regulatory T cells (Tregs) has been translated into the clinic and is currently being tested in transplant recipients and patients suffering from autoimmune diseases. Moreover, building on animal models, it has been widely reported that antigen-specific Tregs are functionally superior to polyclonal Tregs. Among various options to confer target specificity to Tregs, genetic engineering is a particularly timely one as has been demonstrated in the treatment of hematological malignancies where it is in routine clinical use. Genetic engineering can be exploited to express chimeric antigen receptors (CAR) in Tregs, and this has been successfully demonstrated to be robust in preclinical studies across various animal disease models. However, there are several caveats and a number of strategies should be considered to further improve on targeting, efficacy and to understand the in vivo distribution and fate of CAR-Tregs. Here, we review the differing approaches to confer antigen specificity to Tregs with emphasis on CAR-Tregs. This includes an overview and discussion of the various approaches to improve CAR-Treg specificity and therapeutic efficacy as well as addressing potential safety concerns. We also discuss different imaging approaches to understand the in vivo biodistribution of administered Tregs. Preclinical research as well as suitability of methodologies for clinical translation are discussed.

Original languageEnglish
Article number1608
JournalFrontiers in Immunology
Volume11
Early online date24 Jul 2020
DOIs
Publication statusPublished - 24 Jul 2020

Keywords

  • CAR (chimeric antigen receptor)
  • Tregs (regulatory T cells)
  • antigen specific
  • autoimmunity
  • cell therapy
  • regulatory
  • transplantation

Fingerprint

Dive into the research topics of 'The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology'. Together they form a unique fingerprint.

Cite this